PresVu : New Eye Drop For Presbyopia
Mumbai-based Entod Pharmaceuticals has announced that the Drug Controller General of India (DCGI) has approved its new eye drop PresVu, which has been developed to reduce dependency on reading glasses for individuals affected by presbyopia.
- Presbyopia is an age-related condition in which the eyes gradually lose the ability to focus on nearby objects.
- People usually start to develop presbyopia at around the age of 40. According to doctors, spectacles are one of the most effective ways to manage the condition.
- The active ingredient — chemical compounds in medicines that have an effect on the body — in PresVu is Pilocarpine.
- The compound contracts the iris muscles, which control the size of the pupil and help humans see things clearly, thereby enabling one’s eyes to focus better on nearby objects.
- PresVu uses “advanced dynamic buffer technology” — essentially, a base solution — to adapt to the pH level (a scale used to measure how acidic or basic a substance is) of tears.
- This ensures that the eye drop has “consistent efficacy and safety for extended use, keeping in mind that such drops will be used for years at a stretch”.
- PresVu is a prescription-only medicine and its impact is unlikely to last beyond four to six hours. It should not be used by people who have inflammation of the iris.
- Regular use of PresVu may lead to itching and redness, eyebrow pain, and muscle spasms in the eyes.
